Eldsamira Mascarenhas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eldsamira Mascarenhas has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Clarissa Baldotto
Instituto D’Or de Pesquisa e Ensino - Department of Clinical Oncology , Rio de Janeiro
9 shared publications - Vladmir Cláudio Cordeiro de Lima
A.C. Camargo Cancer Center, Sao Paulo, Brazil
9 shared publications - Ana Caroline Zimmer Gelatti
PUC-RS, Porto Alegre, Brazil
6 shared publications Clarissa Mathias
Nucleo de Oncologia da Bahia, Salvador, Brazil
6 shared publications- Gilberto de Castro
Department of Oncology, Hospital Sirio-Libanes, Sao Paulo, SP, Brazil
5 shared publications - Luiz Henrique Araujo
Department of Medical Oncology Instituto Nacional de Câncer Rio de Janeiro Brazil
5 shared publications
Latest Publications
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2600042
Treatment of ALK+ Non–Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)
PURPOSE: ALK rearrangements occur in 5.4% of Brazilian patients with non–small cell lung cancer (NSCLC). Data on treatment patterns, access to ALK inhibitors, and survival outcomes are scarce. MATERIALS AND METHODS: LACOG/GBOT 1918 is a retrospective, observational study that included patients diagnosed with ALK-positive NSCLC between January 2015 and December 2020 in 12 Brazilian public and private centers. Data were extracted from patient records, including clinic-epidemiologic features, diagnosis, ALK testing methods, treatment patterns, and outcomes. Data were analyzed using descriptive statistical methods. RESULTS: A total of 101 patients were enrolled. The median age was 55 years (range, 18-86), and 55.4% were female. Immunohistochemistry was the most frequently used method for ALK testing. The median time from the first symptom to diagnosis was 2 months, from diagnosis to ALK testing 1.7 months, and from diagnosis to treatment initiation 1.7 months. Among patients receiving first-line treatment, only 47.9% received ALK inhibitors (53.9% private v 22.2% public), with crizotinib being the most used. For second-line treatment, 66.0% of patients received ALK inhibitors, with alectinib being the most used (50%). Most treated patients had access to ALK inhibitors in some line of treatment (83.3% private v 72.2% public); however, in the public setting, targeted treatment was restricted to first-generation and second-generation ALK inhibitors. The 3-year overall survival (OS) rate was 82.6% (95% CI, 72.6 to 89.2), with a lower 3-year OS in the public setting (61.4% public v 87.2% private; P = .0279). CONCLUSION: Access to targeted ALK therapy is limited in the public health care system, reflecting poor clinical outcomes. Public health measures are necessary to minimize the differences between these two systems.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2600042
Treatment of ALK+ Non–Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)
PURPOSE: ALK rearrangements occur in 5.4% of Brazilian patients with non–small cell lung cancer (NSCLC). Data on treatment patterns, access to ALK inhibitors, and survival outcomes are scarce. MATERIALS AND METHODS: LACOG/GBOT 1918 is a retrospective, observational study that included patients diagnosed with ALK-positive NSCLC between January 2015 and December 2020 in 12 Brazilian public and private centers. Data were extracted from patient records, including clinic-epidemiologic features, diagnosis, ALK testing methods, treatment patterns, and outcomes. Data were analyzed using descriptive statistical methods. RESULTS: A total of 101 patients were enrolled. The median age was 55 years (range, 18-86), and 55.4% were female. Immunohistochemistry was the most frequently used method for ALK testing. The median time from the first symptom to diagnosis was 2 months, from diagnosis to ALK testing 1.7 months, and from diagnosis to treatment initiation 1.7 months. Among patients receiving first-line treatment, only 47.9% received ALK inhibitors (53.9% private v 22.2% public), with crizotinib being the most used. For second-line treatment, 66.0% of patients received ALK inhibitors, with alectinib being the most used (50%). Most treated patients had access to ALK inhibitors in some line of treatment (83.3% private v 72.2% public); however, in the public setting, targeted treatment was restricted to first-generation and second-generation ALK inhibitors. The 3-year overall survival (OS) rate was 82.6% (95% CI, 72.6 to 89.2), with a lower 3-year OS in the public setting (61.4% public v 87.2% private; P = .0279). CONCLUSION: Access to targeted ALK therapy is limited in the public health care system, reflecting poor clinical outcomes. Public health measures are necessary to minimize the differences between these two systems.
- Open Access
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2600117
Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non–Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT)
PURPOSE: In Brazil, diagnosing and treating non–small cell lung cancer (NSCLC) with actionable molecular alterations pose substantial challenges because of health care disparities. Anaplastic lymphoma kinase (ALK) rearrangements represent a clinically relevant subset with highly effective targeted therapies. However, real-world access to ALK diagnostics and treatments across different Brazilian health care sectors remains inadequately characterized. METHODS: We conducted a cross-sectional survey of Brazilian oncologists between October 2024 and March 2025 to assess the availability of ALK testing and targeted therapies, alongside perceived implementation barriers. Of 197 responses collected, 156 were included in the final analytic cohort. Data were analyzed using descriptive statistics, and categorical variables were reported as proportions with 95% CIs. RESULTS: Within the final analytic cohort (N = 156), 93.9% of the respondents practicing in the private sector (n = 147) reported access to ALK testing, whereas only 43.9% of those practicing in the public health care system (n = 107) had access. Access to ALK-targeted therapies was limited for the public health care population: 7.1% received crizotinib and <2% received newer-generation ALK-targeted therapies available in the first-line setting. By contrast, in the private sector, 75.6% and 60.9% reported access to alectinib and lorlatinib, respectively. Chemotherapy remained predominant in the public health care system. Main barriers included lack of reimbursement (58.3%), insufficient tissue (40.4%), and urgency to initiate treatment (36.5%). CONCLUSION: Despite robust evidence supporting ALK-targeted therapies, this study highlights substantial disparities in access to diagnostics and treatment for ALK-rearranged NSCLC in Brazil, particularly among patients reliant on the public health care system. Findings underscore the need for policies to strengthen testing infrastructure, ensure equitable access to guideline-recommended therapies, and enhance provider education. Addressing these gaps is essential for equitable precision oncology and improved outcomes.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2600117
Open AccessCurrent Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non–Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT)
PURPOSE: In Brazil, diagnosing and treating non–small cell lung cancer (NSCLC) with actionable molecular alterations pose substantial challenges because of health care disparities. Anaplastic lymphoma kinase (ALK) rearrangements represent a clinically relevant subset with highly effective targeted therapies. However, real-world access to ALK diagnostics and treatments across different Brazilian health care sectors remains inadequately characterized. METHODS: We conducted a cross-sectional survey of Brazilian oncologists between October 2024 and March 2025 to assess the availability of ALK testing and targeted therapies, alongside perceived implementation barriers. Of 197 responses collected, 156 were included in the final analytic cohort. Data were analyzed using descriptive statistics, and categorical variables were reported as proportions with 95% CIs. RESULTS: Within the final analytic cohort (N = 156), 93.9% of the respondents practicing in the private sector (n = 147) reported access to ALK testing, whereas only 43.9% of those practicing in the public health care system (n = 107) had access. Access to ALK-targeted therapies was limited for the public health care population: 7.1% received crizotinib and <2% received newer-generation ALK-targeted therapies available in the first-line setting. By contrast, in the private sector, 75.6% and 60.9% reported access to alectinib and lorlatinib, respectively. Chemotherapy remained predominant in the public health care system. Main barriers included lack of reimbursement (58.3%), insufficient tissue (40.4%), and urgency to initiate treatment (36.5%). CONCLUSION: Despite robust evidence supporting ALK-targeted therapies, this study highlights substantial disparities in access to diagnostics and treatment for ALK-rearranged NSCLC in Brazil, particularly among patients reliant on the public health care system. Findings underscore the need for policies to strengthen testing infrastructure, ensure equitable access to guideline-recommended therapies, and enhance provider education. Addressing these gaps is essential for equitable precision oncology and improved outcomes.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500522
Lung Cancer in Women in Brazil: Incidence, Trends, and Overlooked Risk Factors
Lung cancer (LC) incidence and mortality rates are increasing in Brazil, particularly among women. Studies indicate that sex may affect incidence, survival, and treatment response. However, overlooked or unknown risk factors may also play a role in the sex disparities observed. For instance, although smoking is a major risk factor for LC, increasing rates of LC among nonsmoking women in Brazil, and elsewhere, have been observed. Also, traditional gender roles expose women to specific environmental hazards, as they are often expected to perform domestic tasks and thus are more likely to be indoors and exposed to second-hand smoke, air pollution from cooking fuels, and radon. In addition, occupational hazards such as formaldehyde, particularly in hairdressing, disproportionately affect women. This narrative review highlights the disparities associated with LC and female sex in Brazil, and calls for more research on these overlooked risk factors.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500522
Lung Cancer in Women in Brazil: Incidence, Trends, and Overlooked Risk Factors
Lung cancer (LC) incidence and mortality rates are increasing in Brazil, particularly among women. Studies indicate that sex may affect incidence, survival, and treatment response. However, overlooked or unknown risk factors may also play a role in the sex disparities observed. For instance, although smoking is a major risk factor for LC, increasing rates of LC among nonsmoking women in Brazil, and elsewhere, have been observed. Also, traditional gender roles expose women to specific environmental hazards, as they are often expected to perform domestic tasks and thus are more likely to be indoors and exposed to second-hand smoke, air pollution from cooking fuels, and radon. In addition, occupational hazards such as formaldehyde, particularly in hairdressing, disproportionately affect women. This narrative review highlights the disparities associated with LC and female sex in Brazil, and calls for more research on these overlooked risk factors.
- Open Access
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500066
Systematic Review and Meta-Analysis of Lung Cancer Diagnostic Methods by the Brazilian Thoracic Oncology Group (GBOT)
PURPOSE: Although various techniques are available for diagnosing lung cancer (LC), comprehensive literature synthesis for selecting the most appropriate diagnostic method remains lacking. This study aims to synthesize and meta-analyze the diagnostic accuracy of bronchoscopy and transthoracic needle biopsy (TTNB) in LC diagnosis. METHODS: A systematic review was conducted to evaluate the diagnostic accuracy of bronchoscopy and TTNB for LC diagnosis. MEDLINE/PubMed, EMBASE, Web of Science, Cochrane Library, and LILACS were systematically searched to identify relevant studies. We included original diagnostic accuracy studies with over 50 participants comparing bronchoscopy or TTNB to surgical biopsy or clinical follow-up. Data were synthesized using a bivariate diagnostic accuracy random-effects model, and the quality of evidence was assessed using QUADAS-2. RESULTS: The search identified 3,707 bronchoscopy studies, of which two met inclusion criteria, precluding meta-analysis because of high heterogeneity. For TTNB, 1,136 studies were screened, with 20 included. Meta-analysis of TTNB studies revealed pooled sensitivity and specificity of 0.91 (95% CI, 0.90 to 0.93) and 0.99 (95% CI, 0.98 to 1.00), respectively. Likelihood ratios indicated high post-test probability of accurate diagnosis across clinical scenarios. CONCLUSION: TTNB demonstrates good diagnostic accuracy for peripheral lung lesions, but carries notable complication risks. Bronchoscopy, while less sensitive, remains valuable for central lesions and mediastinal evaluation. These findings underscore the need for a tailored diagnostic approach on the basis of lesion characteristics and patient profiles, complemented by multidisciplinary expertise.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500066
Open AccessSystematic Review and Meta-Analysis of Lung Cancer Diagnostic Methods by the Brazilian Thoracic Oncology Group (GBOT)
PURPOSE: Although various techniques are available for diagnosing lung cancer (LC), comprehensive literature synthesis for selecting the most appropriate diagnostic method remains lacking. This study aims to synthesize and meta-analyze the diagnostic accuracy of bronchoscopy and transthoracic needle biopsy (TTNB) in LC diagnosis. METHODS: A systematic review was conducted to evaluate the diagnostic accuracy of bronchoscopy and TTNB for LC diagnosis. MEDLINE/PubMed, EMBASE, Web of Science, Cochrane Library, and LILACS were systematically searched to identify relevant studies. We included original diagnostic accuracy studies with over 50 participants comparing bronchoscopy or TTNB to surgical biopsy or clinical follow-up. Data were synthesized using a bivariate diagnostic accuracy random-effects model, and the quality of evidence was assessed using QUADAS-2. RESULTS: The search identified 3,707 bronchoscopy studies, of which two met inclusion criteria, precluding meta-analysis because of high heterogeneity. For TTNB, 1,136 studies were screened, with 20 included. Meta-analysis of TTNB studies revealed pooled sensitivity and specificity of 0.91 (95% CI, 0.90 to 0.93) and 0.99 (95% CI, 0.98 to 1.00), respectively. Likelihood ratios indicated high post-test probability of accurate diagnosis across clinical scenarios. CONCLUSION: TTNB demonstrates good diagnostic accuracy for peripheral lung lesions, but carries notable complication risks. Bronchoscopy, while less sensitive, remains valuable for central lesions and mediastinal evaluation. These findings underscore the need for a tailored diagnostic approach on the basis of lesion characteristics and patient profiles, complemented by multidisciplinary expertise.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500097
Cost-Effectiveness of Lung Cancer Screening in a High-Risk Population in Brazil
PURPOSE: We aimed to assess whether lung cancer (LC) screening with low-dose computed tomography (LDCT) is cost effective in a high-risk population (current or former smokers—who stopped smoking within <15 years—age 50-80 years, with a smoking history of at least 20 pack-years) in the Brazilian public health setting. METHODS: To estimate the size of the population eligible for screening, we used Brazilian 2020 census data and information provided by the nationwide surveillance system of risk factors for chronic diseases. For comparison, we used a nonscreened population of LC cases from the São Paulo state registry. We characterized patient journeys and estimated direct and indirect costs using the nationwide public health system database, DATASUS, and expert opinion from an ad hoc panel. We used Markov models for economic evaluations that considered treatment costs (in Brazilian currency, R$) and outcomes. RESULTS: Adopting an LC screening strategy with LDCT in this high-risk population would be associated with an incremental cost-effectiveness ratio (ICER) of R$ 133,327 per quality-adjusted life year. For the life year outcome, the ICER was R$ 9,579 per life year gained. For both outcomes, the values were below the cost-effectiveness threshold considered (three times the per-capita gross domestic product, which corresponds to R$ 143,406.06 or $24,735.99 US dollars). CONCLUSION: Our study confirms that implementing LC screening with LDCT in a high-risk population is cost effective in the Brazilian public health system.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500097
Cost-Effectiveness of Lung Cancer Screening in a High-Risk Population in Brazil
PURPOSE: We aimed to assess whether lung cancer (LC) screening with low-dose computed tomography (LDCT) is cost effective in a high-risk population (current or former smokers—who stopped smoking within <15 years—age 50-80 years, with a smoking history of at least 20 pack-years) in the Brazilian public health setting. METHODS: To estimate the size of the population eligible for screening, we used Brazilian 2020 census data and information provided by the nationwide surveillance system of risk factors for chronic diseases. For comparison, we used a nonscreened population of LC cases from the São Paulo state registry. We characterized patient journeys and estimated direct and indirect costs using the nationwide public health system database, DATASUS, and expert opinion from an ad hoc panel. We used Markov models for economic evaluations that considered treatment costs (in Brazilian currency, R$) and outcomes. RESULTS: Adopting an LC screening strategy with LDCT in this high-risk population would be associated with an incremental cost-effectiveness ratio (ICER) of R$ 133,327 per quality-adjusted life year. For the life year outcome, the ICER was R$ 9,579 per life year gained. For both outcomes, the values were below the cost-effectiveness threshold considered (three times the per-capita gross domestic product, which corresponds to R$ 143,406.06 or $24,735.99 US dollars). CONCLUSION: Our study confirms that implementing LC screening with LDCT in a high-risk population is cost effective in the Brazilian public health system.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400323
Gender Equity and Workplace Mistreatment in Oncology: Results From a Survey by the Brazilian Society of Clinical Oncology
PURPOSE: There are no available data concerning gender equity and workplace mistreatment within the field of oncology in Brazil. The Brazilian Society of Clinical Oncology (Sociedade Brasileira de Oncologia Clínica [SBOC]) performed a survey study to present and discuss this subject and gain insights into strategies that would mitigate gender inequities. MATERIALS AND METHODS: A 24-question survey in Portuguese, assessing demographics, professional context, achievements, workplace mistreatment, parenthood, and gender balance in the workplace, was developed and administered by the SBOC Women's Leadership Committee. SBOC members were invited to participate by e-mail. RESULTS: Among the 2,125 SBOC members, 146 women (72%) and 56 men (28%) participated in the survey. Approximately 87.5% of men versus 65.5% of women believed that they had equal rights ( P < .002) at their workplace. Chiefs of oncology departments were more often men than women (30.4% v 13.7%, P < .006). Furthermore, 60.8% of men versus 85.1% of women ( P = .0003) believed that a specific workplace guideline regarding gender equity should exist. Only 29.5% of women versus 98.2% of men ( P < .0001) believed that they did not experience gender discrimination throughout their careers. Approximately 50% of women versus 21% of men reported experiencing moral harassment at work ( P = .0002), whereas 24% of women and 7% of men reported sexual harassment ( P = .005). Multivariable logistic regression confirmed the significant results of univariable analysis when adjusted for age group and holding a department chief position. CONCLUSION: Our data show an alarming level of sexual and moral harassment and gender inequity experienced by SBOC members, highlighting the urgent need for programs to address these situations.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400323
Gender Equity and Workplace Mistreatment in Oncology: Results From a Survey by the Brazilian Society of Clinical Oncology
PURPOSE: There are no available data concerning gender equity and workplace mistreatment within the field of oncology in Brazil. The Brazilian Society of Clinical Oncology (Sociedade Brasileira de Oncologia Clínica [SBOC]) performed a survey study to present and discuss this subject and gain insights into strategies that would mitigate gender inequities. MATERIALS AND METHODS: A 24-question survey in Portuguese, assessing demographics, professional context, achievements, workplace mistreatment, parenthood, and gender balance in the workplace, was developed and administered by the SBOC Women's Leadership Committee. SBOC members were invited to participate by e-mail. RESULTS: Among the 2,125 SBOC members, 146 women (72%) and 56 men (28%) participated in the survey. Approximately 87.5% of men versus 65.5% of women believed that they had equal rights ( P < .002) at their workplace. Chiefs of oncology departments were more often men than women (30.4% v 13.7%, P < .006). Furthermore, 60.8% of men versus 85.1% of women ( P = .0003) believed that a specific workplace guideline regarding gender equity should exist. Only 29.5% of women versus 98.2% of men ( P < .0001) believed that they did not experience gender discrimination throughout their careers. Approximately 50% of women versus 21% of men reported experiencing moral harassment at work ( P = .0002), whereas 24% of women and 7% of men reported sexual harassment ( P = .005). Multivariable logistic regression confirmed the significant results of univariable analysis when adjusted for age group and holding a department chief position. CONCLUSION: Our data show an alarming level of sexual and moral harassment and gender inequity experienced by SBOC members, highlighting the urgent need for programs to address these situations.
- Open Access
- 25 April 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2100333
Non–Small-Cell Lung Cancer With CNS Metastasis: Disparities From a Real-World Analysis (GBOT-LACOG 0417)
PURPOSE: Despite the advances in the approach to non–small-cell lung cancer (NSCLC) with CNS metastasis, access to timely diagnosis and treatment may not be optimal in many instances. Our main objective was to describe a cohort of patients with NSCLC with brain metastases from public and private cancer centers, and the differences between patients' presentation, treatment, and outcomes. METHODS: GBOT-LACOG 0417 is a multi-institutional retrospective cohort study of patients diagnosed with NSCLC and CNS metastasis in Brazil. All patients had confirmed diagnosis of NSCLC between January 2010 and December 2015. CNS metastases were identified by imaging. RESULTS: A total of 273 patients were included. Patients treated at public institutions were more often Black or Brown (38.8% v 15.4%), current or former smoker (88.6% v 60.0%), of squamous cell histology (25.0% v 9.1%), EGFR- and ALK-negative (95.9% v 74.9%), and were less frequently assessed by using brain magnetic resonance imaging (38.8% v 83.6%). At public institutions, patients were more often symptomatic (78.1% v 44.6%) and had worse performance status (Eastern Cooperative Oncology Group 2 or higher 61.5% v 10.3%). CNS metastases were larger (median size 25 v 15 mm) and more often surrounded by edema (67.7% v 55.2%) at public institutions. Patients at public institutions were more frequently treated with whole-brain radiation therapy (72.9% v 45.4%) and less frequently with radiosurgery (6.3% v 24.1%). Among patients from private care, median overall survival was 24.2 months (95% CI, 20.0 to 30.6), significantly higher than in public care (median 12.1 months; 95% CI, 6.7 to 13.6; P < .001). CONCLUSION: Our results demonstrate the discrepancy between public and private health care system in the critical setting of patients with CNS metastasis from NSCLC.
- 25 April 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2100333
Open AccessNon–Small-Cell Lung Cancer With CNS Metastasis: Disparities From a Real-World Analysis (GBOT-LACOG 0417)
PURPOSE: Despite the advances in the approach to non–small-cell lung cancer (NSCLC) with CNS metastasis, access to timely diagnosis and treatment may not be optimal in many instances. Our main objective was to describe a cohort of patients with NSCLC with brain metastases from public and private cancer centers, and the differences between patients' presentation, treatment, and outcomes. METHODS: GBOT-LACOG 0417 is a multi-institutional retrospective cohort study of patients diagnosed with NSCLC and CNS metastasis in Brazil. All patients had confirmed diagnosis of NSCLC between January 2010 and December 2015. CNS metastases were identified by imaging. RESULTS: A total of 273 patients were included. Patients treated at public institutions were more often Black or Brown (38.8% v 15.4%), current or former smoker (88.6% v 60.0%), of squamous cell histology (25.0% v 9.1%), EGFR- and ALK-negative (95.9% v 74.9%), and were less frequently assessed by using brain magnetic resonance imaging (38.8% v 83.6%). At public institutions, patients were more often symptomatic (78.1% v 44.6%) and had worse performance status (Eastern Cooperative Oncology Group 2 or higher 61.5% v 10.3%). CNS metastases were larger (median size 25 v 15 mm) and more often surrounded by edema (67.7% v 55.2%) at public institutions. Patients at public institutions were more frequently treated with whole-brain radiation therapy (72.9% v 45.4%) and less frequently with radiosurgery (6.3% v 24.1%). Among patients from private care, median overall survival was 24.2 months (95% CI, 20.0 to 30.6), significantly higher than in public care (median 12.1 months; 95% CI, 6.7 to 13.6; P < .001). CONCLUSION: Our results demonstrate the discrepancy between public and private health care system in the critical setting of patients with CNS metastasis from NSCLC.
- Open Access
- 13 December 2020
- Published by Wiley in Thoracic Cancer
- Vol. 12 (5) , 580-587
Comprehensive genomic profiling of Brazilian non‐small cell lung cancer patients (GBOT 0118/LACOG0418)
Background: The aim of this study was to carry out a descriptive analysis of the somatic genetic profile and co‐occurring mutations of non‐small cell lung cancer (NSCLC) samples from patients tested with comprehensive genomic profiling (CGP).Methods: This was a retrospective cross‐sectional study of patients diagnosed with NSCLC from 2013 to 2018 in Brazil and whose samples were submitted to CGP (FoundationOne or FoundationACT) using either tumor or circulating tumor DNA (ctDNA) from plasma.Results: We recovered 513 CGP results from patients, 457 (89.1%) of which were from tumors and 56 (10.9%) from plasma. The median age of patients was 64 years old, of which 51.6% were males. TP53 mutations were identified in 53.6% of tumor samples, KRAS mutations in 24.2%, EGFR activating mutations were detected in 22.5%, STK11 mutations in 11.6%, PIK3CA mutations in 8.8%, ALK rearrangements in 5.4%, BRAF mutations in 5.2%, and ERBB2 alterations in 4.9%. The most commonly comutated gene was TP53. TP53 p.R337H was observed in 4.3% of samples and was associated with somatic mutations in EGFR and ERBB2 (P < 0.00001). Tumor mutational burden (TMB) analysis was available for 80.5% of samples tested, and 5.5% of samples had high TMB (≥ 20 mutations/Mb).In conclusion, this retrospective analysis of genomic data from NSCLC patients obtained by CGP showed that common abnormalities such as EGFR mutations and ALK rearrangements had similar frequency to those previously described by other groups using others strategies. Additionally, our data confirm an association between TP53 p.R337H, supposedly germline in nature, and somatic mutations in genes of the HER family.Key points: Significant findings of the study: This is the first report of the prevalence of driver mutations in Brazilian NSCLC patients using comprehensive genomic profiling (CGP). The frequency of the most common driver mutations in this population was similar to that previously described in Brazil. What this study adds: TP53 was the most commonly comutated gene across samples. TP53 p.R337H was associated with somatic mutations in EGFR and ERBB2. Most samples had low TMB; only 5.5% of samples had high TMB.
- 13 December 2020
- Published by Wiley in Thoracic Cancer
- Vol. 12 (5) , 580-587
Open AccessComprehensive genomic profiling of Brazilian non‐small cell lung cancer patients (GBOT 0118/LACOG0418)
Background: The aim of this study was to carry out a descriptive analysis of the somatic genetic profile and co‐occurring mutations of non‐small cell lung cancer (NSCLC) samples from patients tested with comprehensive genomic profiling (CGP).Methods: This was a retrospective cross‐sectional study of patients diagnosed with NSCLC from 2013 to 2018 in Brazil and whose samples were submitted to CGP (FoundationOne or FoundationACT) using either tumor or circulating tumor DNA (ctDNA) from plasma.Results: We recovered 513 CGP results from patients, 457 (89.1%) of which were from tumors and 56 (10.9%) from plasma. The median age of patients was 64 years old, of which 51.6% were males. TP53 mutations were identified in 53.6% of tumor samples, KRAS mutations in 24.2%, EGFR activating mutations were detected in 22.5%, STK11 mutations in 11.6%, PIK3CA mutations in 8.8%, ALK rearrangements in 5.4%, BRAF mutations in 5.2%, and ERBB2 alterations in 4.9%. The most commonly comutated gene was TP53. TP53 p.R337H was observed in 4.3% of samples and was associated with somatic mutations in EGFR and ERBB2 (P < 0.00001). Tumor mutational burden (TMB) analysis was available for 80.5% of samples tested, and 5.5% of samples had high TMB (≥ 20 mutations/Mb).In conclusion, this retrospective analysis of genomic data from NSCLC patients obtained by CGP showed that common abnormalities such as EGFR mutations and ALK rearrangements had similar frequency to those previously described by other groups using others strategies. Additionally, our data confirm an association between TP53 p.R337H, supposedly germline in nature, and somatic mutations in genes of the HER family.Key points: Significant findings of the study: This is the first report of the prevalence of driver mutations in Brazilian NSCLC patients using comprehensive genomic profiling (CGP). The frequency of the most common driver mutations in this population was similar to that previously described in Brazil. What this study adds: TP53 was the most commonly comutated gene across samples. TP53 p.R337H was associated with somatic mutations in EGFR and ERBB2. Most samples had low TMB; only 5.5% of samples had high TMB.
- 1 November 2020
- Published by Elsevier in Clinical Lung Cancer
- Vol. 21 (6) , e511-e515
Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non–Small-Cell Lung Cancer
- 1 November 2020
- Published by Elsevier in Clinical Lung Cancer
- Vol. 21 (6) , e511-e515
Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non–Small-Cell Lung Cancer